Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$47.43 - $84.23 $13.2 Million - $23.4 Million
-277,694 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$73.06 - $97.7 $42,520 - $56,861
582 Added 0.21%
277,694 $23.6 Million
Q1 2021

May 10, 2021

SELL
$70.43 - $97.42 $11.2 Million - $15.4 Million
-158,455 Reduced 36.38%
277,112 $23.3 Million
Q4 2020

Feb 12, 2021

SELL
$48.9 - $75.26 $4.1 Million - $6.31 Million
-83,887 Reduced 16.15%
435,567 $32.8 Million
Q3 2020

Nov 10, 2020

BUY
$37.23 - $50.97 $162,062 - $221,872
4,353 Added 0.85%
519,454 $25.7 Million
Q2 2020

Aug 12, 2020

BUY
$28.78 - $46.83 $2.88 Million - $4.68 Million
99,929 Added 24.07%
515,101 $19.8 Million
Q1 2020

May 08, 2020

BUY
$25.53 - $70.14 $5.4 Million - $14.8 Million
211,417 Added 103.76%
415,172 $12.8 Million
Q4 2019

Feb 13, 2020

BUY
$54.18 - $65.64 $2.44 Million - $2.96 Million
45,024 Added 28.36%
203,755 $11.1 Million
Q3 2019

Nov 14, 2019

BUY
$58.58 - $83.91 $1.8 Million - $2.58 Million
30,733 Added 24.01%
158,731 $9.92 Million
Q2 2019

Aug 07, 2019

BUY
$63.59 - $78.71 $3.47 Million - $4.29 Million
54,500 Added 74.15%
127,998 $0
Q1 2019

May 08, 2019

BUY
$50.75 - $80.54 $178,589 - $283,420
3,519 Added 5.03%
73,498 $0
Q4 2018

Feb 14, 2019

SELL
$52.18 - $67.93 $7,357 - $9,578
-141 Reduced 0.2%
69,979 $3.93 Million
Q3 2018

Nov 07, 2018

BUY
$38.13 - $68.37 $353,045 - $633,037
9,259 Added 15.21%
70,120 $0
Q2 2018

Aug 02, 2018

SELL
$27.62 - $44.51 $46,180 - $74,420
-1,672 Reduced 2.67%
60,861 $0
Q1 2018

May 02, 2018

BUY
$26.05 - $34.5 $957,650 - $1.27 Million
36,762 Added 142.65%
62,533 $0
Q4 2017

Jan 16, 2018

BUY
$24.5 - $36.01 $631,389 - $928,013
25,771
25,771 $0

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $7.44B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track This Portfolio

Track Wasatch Advisors Inc Portfolio

Follow Wasatch Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wasatch Advisors Inc with notifications on news.